1. N17 Frequency of infliximab-induced skin lesions and their impact on quality of life in inflammatory bowel disease patients treated with infliximab. (25th January 2019) Authors: Bobnar Sekulic, C; Polanc, T; Koren, U; Kurent, T; Smrekar, N; Hanžel, J; Drobne, D; Novak, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S564 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P672 Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodies. (30th January 2023) Authors: Anjie, S; Hanžel, J; Gecse, K B; D'Haens, G R; Brandse, J F Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i803 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease. (30th January 2023) Authors: Pintar, S; Hanžel, J; Smrekar, N; Koželj, M; Drobne, D; Kurent, T; Štabuc, B; Novak, G Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis. (30th January 2023) Authors: Wang, Z; Afif, W; Hanžel, J; Kobayashi, T; Papamichail, K; Roblin, X; Peyrin-Biroulet, L; Vermeire, S; Dreesen, E Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i925 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗